PCNA-I1

Catalog No.S4476 Batch:S447601

Print

Technical Data

Formula

C17H14N2O2S

Molecular Weight 310.37 CAS No. 444930-42-1
Solubility (25°C)* In vitro DMSO 62 mg/mL (199.76 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
1%DMSO 40%PEG300 5%TWEEN80 54%ddH2O
1.0mg/ml Taking the 1 mL working solution as an example, add 10 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 540 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description PCNA-I1 is a selective inhibitor of proliferating cell nuclear antigen (PCNA, a potential anticancer target). PCNA-I1 selectively binds to PCNA trimers with Kd of ~0.2 to 0.4 μM. PCNA-I1 inhibits the growth of tumor cells of various tissue types with IC50 of ~0.2 μM. PCNA-I1 induces DNA damage and apoptosis in both LNCaP and PC-3 cells. PCNA-I1 also induces autophagy in PC-3 cells.
Targets
PCNA trimers [1]
(Cell-free assay)
0.2 to 0.4 μM(Kd)
In vitro

PCNA-I1 prevents the transportation of the Proliferating Cell Nuclear Antigen (PCNA) to the cytoplasm by stabilizing its trimer form in the nucleus, thus inhibits SARS-CoV-2 replication.[3]

Protocol (from reference)

Cell Assay:

[3]

  • Cell lines

    Vero E6 cells

  • Concentrations

    0.1, 1, 10 and 100 µM

  • Incubation Time

    96 h

  • Method

    Lung tissue sections A plaque assay was performed. Briefly, after seeding, Vero E6 (8 × 105 cells per well, 6-well plates) were incubated overnight and infected with 200 PFU per well. PCNA-I1 or Verdinexor were added at final concentrations of 0.5 µM or 0.1 µM and 0.1 µM or 1 µM, in overlays composed of DMEM supplemented with 10% FBS plus carboxymethylcellulose sodium salt 2%, immediately post-viral adsorption. A MTT cell proliferation assay was done to verify the toxicity of the drugs. After four days, cells were fixed with formaldehyde and stained with crystal violet to count plaques.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.